Although specific combination data in CCA remain sparse, this mechanistic rationale strongly supports the integration of ferroptosis-inducing therapies (targeting ACSL4, GPX4 or other ferroptosis regulators) with ICIs in CCA (161). The gene discussed is ACSL4; the disease is cholangiocarcinoma.